← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Omeros Corporation
Seattle, WA
$12,840,283
Total funding
15
Grants
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,840,283 · 15
By mechanism
U01$6,689,019 · 1
R44$3,386,305 · 4
R43$2,764,959 · 10
Investigators at Omeros Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
PDE7 Inhibitor for the Treatment of Cocaine Use Disorder$4,461,636
U01 · FY2025 · DA
PDE7 Inhibitor for the Treatment of Cocaine Use Disorder$1,382,131
U01 · FY2023 · DA
PDE7 Inhibitor for the Treatment of Cocaine Use Disorder$845,252
U01 · FY2024 · DA
Development of NMUR2 Antagonists as Novel Analgesics$524,835
R44 · FY2012 · DA
Development of NMUR2 Antagonists as Novel Analgesics$517,024
R44 · FY2013 · DA
MASP-2 Therapy for Macular Degeneration$487,011
R44 · FY2010 · EY
G-Protein-Coupled Receptors As Drug Targets for Anxiety$450,000
R44 · FY2008 · MH
G-Protein-Coupled Receptors As Drug Targets for Anxiety$450,000
R44 · FY2004 · MH
Novel 5-HT treatments for METH post-addiction therapy$425,631
R44 · FY2005 · DA
Novel 5-HT treatments for METH post-addiction therapy$358,143
R44 · FY2006 · DA
Monoclonal Antibodies for Orphan GPCRs in the CNS$348,510
R43 · FY2012 · MH
Monoclonal Antibodies for Orphan GPCRs in the CNS$348,510
R43 · FY2013 · MH
A novel therapeutic target for OA that restores IGF-1 responses$334,600
R43 · FY2009 · AR
Universal High Throughput GPCR Screening Assay$239,449
R43 · FY2010 · MH
Universal High Throughput GPCR Screening Assay$237,427
R43 · FY2009 · MH
Development of MASP-2 MoAbs for the treatment of diabetic nephropathy$198,383
R43 · FY2010 · DK
Novel therapy for osteoporosis$193,888
R43 · FY2009 · AG
MASP-2 Antibodies for Diabetic Neuropathy$193,002
R43 · FY2012 · NS
MASP-2 Therapy for Macular Degeneration$173,661
R44 · FY2011 · EY
A Novel Therapeutic Target for OA that Restores IGF-1 Responses$148,400
R43 · FY2009 · AR